- Home
- DYAI vs BIVI Comparison
DYAI vs BIVI Comparison
Compare DYAI & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- BIVI
- Stock Information
- Founded
- DYAI 1979
- BIVI 2013
- Country
- DYAI United States
- BIVI United States
- Employees
- DYAI N/A
- BIVI N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- DYAI Health Care
- BIVI Health Care
- Exchange
- DYAI Nasdaq
- BIVI Nasdaq
- Market Cap
- DYAI 54.4M
- BIVI 49.8M
- IPO Year
- DYAI 2004
- BIVI N/A
- Fundamental
- Price
- DYAI $1.50
- BIVI $2.24
- Analyst Decision
- DYAI Strong Buy
- BIVI Strong Buy
- Analyst Count
- DYAI 1
- BIVI 1
- Target Price
- DYAI $6.00
- BIVI $30.00
- AVG Volume (30 Days)
- DYAI 213.3K
- BIVI 1.1M
- Earning Date
- DYAI 11-12-2024
- BIVI 02-11-2025
- Dividend Yield
- DYAI N/A
- BIVI N/A
- EPS Growth
- DYAI N/A
- BIVI N/A
- EPS
- DYAI N/A
- BIVI N/A
- Revenue
- DYAI $3,364,548.00
- BIVI N/A
- Revenue This Year
- DYAI $51.30
- BIVI N/A
- Revenue Next Year
- DYAI $73.26
- BIVI N/A
- P/E Ratio
- DYAI N/A
- BIVI N/A
- Revenue Growth
- DYAI 13.82
- BIVI N/A
- 52 Week Low
- DYAI $0.93
- BIVI $1.04
- 52 Week High
- DYAI $2.67
- BIVI $33.10
- Technical
- Relative Strength Index (RSI)
- DYAI 42.12
- BIVI 47.36
- Support Level
- DYAI $1.45
- BIVI $1.90
- Resistance Level
- DYAI $1.79
- BIVI $2.27
- Average True Range (ATR)
- DYAI 0.24
- BIVI 0.20
- MACD
- DYAI -0.05
- BIVI 0.02
- Stochastic Oscillator
- DYAI 7.25
- BIVI 50.30
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.